BPC-157 is a synthetic fifteen amino acid peptide. No regulator has approved it anywhere, yet it carries an unusually large animal literature and a very small human one. For example, a 2025 systematic review of the orthopaedic literature identified 36 studies published between 1993 and 2024, and almost all of them are animal work. The human evidence that exists comes from trials in inflammatory bowel disease run in the early 2000s, not from anything in muscle, tendon or joint research.
So that gap is the whole story of this compound. On paper the enthusiasm is real, the petri dish and rodent data are extensive, and the human data is thin in a way that people rarely state plainly. What follows separates the three, because the difference decides how much weight each claim deserves.
In This Guide
- BPC-157: what it actually is
- The animal research, and what it shows
- The human data that exists
- Claims the research does not support
- Safety, and the specific concerns regulators name
- Legal and anti-doping status
- FAQ
BPC-157: what it actually is
The name stands for body protection compound, since it comes from a fragment of a protein found in human gastric juice. It is a pentadecapeptide, meaning fifteen amino acids. Researchers study a stable synthetic version rather than extracting it from a natural source.
| Property | What is known |
|---|---|
| Structure | Synthetic pentadecapeptide, fifteen amino acids, derived from a gastric juice protein fragment |
| Half-life | Under 30 minutes in animal studies. Nobody has published a human pharmacokinetic study, so there is no human figure at all |
| Forms studied | Injectable in most animal work; oral and rectal forms used in the human inflammatory bowel disease trials |
| Approval status | Not approved as a medicine in the United States, the EU or the UK |
| Sport status | Prohibited. Named explicitly in WADA’s S0 category of non-approved substances |
| Regulatory flag | Listed on the FDA page of bulk drug substances for compounding that may present significant safety risks |
The half-life figure deserves its own sentence, because it is the most misquoted number in this category. That under 30 minute figure comes from rodent and dog work, not from people. Yet people repeat it online as though someone had measured it in humans. So our peptide half-life chart marks it as animal data.
The animal research, and what it shows
In practice, the animal literature is broad and consistent in direction. Across the models they used, researchers report that BPC-157 accelerates healing in tendon, ligament, muscle, bone, gut lining and nerve tissue, and that it interacts with the nitric oxide system and with growth factor signalling such as VEGF, which is the proposed explanation for the vascular effects often described.
Two things about that body of work are worth holding in mind at the same time. First, it is more extensive than most compounds in this category, which is why the compound has a reputation at all. Second, it is animal work: rodent models with induced injuries, small numbers, and outcome measures that are easier to show a difference in than a human clinical endpoint like return to sport.
People also compare it with TB-500 constantly, although the two work through different biology. If you want that comparison in detail, the BPC-157 vs TB-500 page sets them side by side.
The human data that exists
There is more human data than the phrase “no human trials” suggests, although it is narrower than the internet implies.
- Inflammatory bowel disease. In the early 2000s, researchers ran phase II clinical work, giving BPC-157 by injection and rectally. The published reviews describe it as having reached clinical phase II, and it is the only substantial human dataset for this compound.
- Everything else. But tendon, muscle, joint and nerve outcomes rest on animal models. Case reports and clinic write-ups exist, yet they are not controlled trials, whatever the marketing around them says.
However, if you want to check the registry yourself rather than take my word for it, search the term on ClinicalTrials.gov. What you will find is the point of this section: for a compound this widely discussed, the registered human trial record is remarkably empty.
Claims the research does not support
| Claim | State of the evidence |
|---|---|
| Heals tendon and ligament injuries in humans | Not demonstrated. Animal models show tendon healing only |
| Builds muscle or increases strength | No human evidence. Not a growth or anabolic agent, and no controlled human work studies it as one |
| Repairs the gut in humans | The closest thing to human evidence, from the early inflammatory bowel disease work, and it is not the same as evidence for general gut support in healthy people |
| Works systemically after oral use | Unclear. The bowel trials used oral and rectal dosing, and nobody has published human pharmacokinetics |
| Is safe because it is a fragment of a human protein | An origin story, not a safety dataset. See the regulatory flag below |
| Has a known human half-life of two hours | Wrong number and wrong species. The published figure is under 30 minutes, in animals |
Safety, and the specific concerns regulators name
So far there is no human safety database of the kind that comes with an approved medicine: no defined dose range with adverse event rates, no long-term follow-up, no interaction data. But there is a regulator’s stated concern instead.
For its part, the FDA lists BPC-157 among the bulk drug substances for use in compounding that may present significant safety risks. Because the stated reason is specific rather than general, it is worth quoting: compounded drugs containing it may pose risk for immunogenicity for certain routes of administration, and may have complexities around peptide-related impurities and characterisation of the active ingredient. In plain terms, the concern is that repeated doses of a foreign peptide can provoke an immune response, and that the purity profile of unapproved supply is not controlled.
There is one more thing worth saying plainly, since it applies to this whole category: nothing guarantees that the vial contains the peptide named on the label. For a compound with no approved manufacturing standard, the only check available to a buyer is a certificate of analysis matched to the batch.
Legal and anti-doping status
- Not an approved drug. No regulator has approved BPC-157 for human use, which means no approved product, no approved indication, and no approved dose.
- Sport. The World Anti-Doping Agency names BPC-157 explicitly in its S0 class of non-approved substances, so it sits on the prohibited list. Meanwhile, USADA has published separately on the risk this creates for athletes, including the risk of an inadvertent positive test.
- Compounding. Because the FDA’s peptide categorisation has been moving through 2026, a group of peptides came off the Category 2 list in April. Yet removal from a flag list is not approval, and it does not make a product legal to sell as a supplement. Check the current FDA page before relying on any status you read about.
For the wider picture of how peptides, growth hormone and HCG differ in form, storage and verification, see the guide to peptides, HGH and HCG. You will also find further guides in the peptides section.
FAQ
Is BPC-157 approved for human use?
No. The FDA, the EMA and the MHRA have not approved it as a medicine, so no approved product exists. Sellers market it as a research chemical and people discuss it as a supplement, which is not the same as approval for human use.
Have there been human trials of BPC-157?
Yes, but only in one area. In the early 2000s, researchers ran phase II work in inflammatory bowel disease, using injected and rectal dosing. Beyond that, tendon, muscle, joint and nerve claims rest on animal studies, and the registered human trial record is otherwise empty.
What is the half-life of BPC-157?
Under 30 minutes, measured in rats and dogs. Nobody has published a human pharmacokinetic study, so the human half-life is unknown. But the commonly quoted two hour figure is wrong on both the number and the species.
Does BPC-157 build muscle?
No human evidence supports that, and nobody studies it as an anabolic or growth agent. Instead, the literature is about tissue repair in animal models and gut inflammation in humans.
Is BPC-157 banned in sport?
Yes. WADA names it in the prohibited list under S0, the class for non-approved substances, and USADA has warned athletes about it.
Why does the FDA flag it?
The agency lists it among bulk drug substances for compounding that may present significant safety risks, citing potential immunogenicity for certain routes of administration and difficulties with peptide impurities and characterising the active ingredient.
Can I take it orally?
The inflammatory bowel disease trials used oral and rectal dosing, so researchers have studied the route in that setting. Nobody has published human pharmacokinetics, so how much reaches circulation after oral use is unknown, and digestion breaks the peptide down.
What should I check if I am looking at a product?
Check whether a batch-matched certificate of analysis exists, whether the certificate states the purity method, and whether the seller makes claims that the published research does not support. Claims that outrun the evidence are the most reliable signal of a bad supplier.
Last reviewed: October 2026 by Julian Hart. This page is educational and is not medical advice, and it is not an endorsement or an instruction for using any substance. No regulator has approved BPC-157 for human use, and anything involving dosing or a health condition belongs with a qualified clinician.
Sources
- McGuire FP, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 36 studies, 1993 to 2024.
- McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157. 2025.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157, including the phase II clinical work in inflammatory bowel disease. 2012.
- He L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC-157 in rats and dogs. 2022. Elimination half-life under 30 minutes.
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, including the stated concerns for BPC-157.
- WADA. The Prohibited List, S0 non-approved substances, which names BPC-157.
- USADA. BPC-157: experimental peptide creates risk for athletes.
- ClinicalTrials.gov search for BPC-157, for the registry record cited in this article.
